Bardoxolone Methyl 2017-06-09T19:29:59+00:00

Clinical Trials

August 18, 2015

Bardoxolone Methyl Evaluation in Patients With Pulmonary Arterial Hypertension (PAH) – LARIAT

  • Study Sponsor: Reata Pharmaceuticals, Inc.
  • Institution: Reata Pharmaceuticals
  • Start Date: Wednesday, January 1, 2014
  • End Date: Saturday, December 31, 2016
  • Design: Placebo-controlled
    Background treatment allowed
  • Age range (years): from 18 to 75
  • Type of PH
    • All PAH (Group 1 PH)
  • Study Duration for individual patient: 16 weeks
  • Contact: https://reatapharma.com/programs/ph-ild/
  • Listing on clinicaltrials.gov